Viewing Study NCT00783367

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:33 AM
Ignite Modification Date: 2026-07-04 @ 12:35 AM
Study NCT ID: NCT00783367
Status: COMPLETED
Last Update Posted: 2023-03-30
First Post: 2008-10-30
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Sponsor: Abramson Cancer Center at Penn Medicine
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Follicular Lymphoma View
None Marginal Zone B-Cell Lymphoma View
None MALT Lymphoma View
None Lymphoma of Mucosa-Associated Lymphoid Tissue View
None Lymphoma, Small Lymphocytic View
None Waldenstrom Macroglobulinemia View
None Mantle-Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Revlimid View
None Celgene brand of lenalidomide View
None lenalidomide View
None Rituxan View
None CD20 antibody, rituximab View
None rituximab View
None Follicular Lymphoma View
None Marginal Zone B-Cell Lymphoma View
None Lymphoma, Small Lymphocytic View
None Waldenstrom Macroglobulinemia View
None Mantle-Cell Lymphoma View
None Antigens, CD20 View
None refractory View
None resistantRefractory/progressive lymphoma less than 6 months from first rituximab dose … View
None Previously treated View
None Treated with rituximab View